This is recommended to consider as first-line therapy for gout

The correct option is Allopurinol.

Gout is a painful form of inflammatory arthritis caused by the deposition of monosodium urate crystals in joints and tissues. This deposition occurs when there is an excess of uric acid in the blood (hyperuricemia). To manage gout effectively over the long term, urate-lowering therapy (ULT) is indicated to reduce and maintain serum urate levels below target thresholds.

Mechanism of Action:
Allopurinol is a xanthine oxidase inhibitor. It works by blocking the enzyme xanthine oxidase, which is responsible for the sequential oxidation of hypoxanthine to xanthine, and subsequently xanthine to uric acid. By inhibiting this enzyme, allopurinol effectively decreases the production of uric acid in the body.

First-Line Recommendation:
Clinical guidelines, such as those from the American College of Rheumatology (ACR), strongly recommend Allopurinol as the preferred first-line agent for urate-lowering therapy in all patients with gout, including those with moderate-to-severe chronic kidney disease (CKD). It is preferred over other agents due to its established efficacy, safety profile when properly titrated, and cost-effectiveness.

Comparison with Other Options:
• Febuxostat is also a xanthine oxidase inhibitor but is typically reserved as an alternative (second-line) for patients who cannot tolerate allopurinol or in whom allopurinol has failed to achieve target serum urate levels, partly due to cardiovascular safety considerations.
• Probenecid and Benzbromarone are uricosuric agents, which lower uric acid by increasing its excretion in the urine. They are generally considered alternative or adjunctive therapies and are less preferred as initial monotherapy, especially in patients with impaired renal function or a history of kidney stones.